TEVA $57.5M Stalking-Horse Bid: BXCL501 Nov 14 PDUFA

Teva Pharmaceuticals (TEVA) is now the lead bidder for BXCL501, the dexmedetomidine sublingual film that could become the first FDA-approved at-home treatment for acute agitation in schizophrenia and bipolar disorder. The FDA’s PDUFA deadline to decide on the application is November 14, 2026, and the $57.5 million Teva has put on the table now rides on that decision.

BioXcel Therapeutics (BTAI) filed for Chapter 11 bankruptcy on August 27, 2026, and its stock fell roughly 62% to $0.27 the next day. Teva stepped in as the stalking-horse bidder in a court-supervised 363 auction, offering $57.5 million upfront plus up to $67.5 million in contingent payments tied to the timing of FDA approval and to future sales milestones. The bid sets the floor, and higher bidders can still emerge before the bankruptcy court signs off on a sale.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, a sedative best known from hospital ICUs. BioXcel already sells it as IGALMI, an under-the-tongue film approved for acute agitation but only when a healthcare provider administers it. The pending sNDA would extend that label to at-home, outpatient use, reaching a much larger population. Schizophrenia affects roughly 2.8 million US adults and bipolar disorder around 4.4 million, and agitation episodes frequently end in emergency room visits or hospitalization. IGALMI is already on the market, but its healthcare-setting restriction caps how many patients can use it.

The at-home label is not a given. IGALMI carries warnings for low blood pressure, slowed heart rate, and QT interval prolongation, and patients are told to avoid driving for at least eight hours after a dose. Whether the FDA is comfortable with unsupervised dosing is the central question of the November review.

For Teva, this is a distressed-asset catalyst rather than a routine FDA one. The contingent payments are structured to shrink if approval slips past the November date, so the milestone waterfall is directly exposed to FDA timing. Teva shares closed at $36.44 the day the bid was announced, essentially flat, because for a company of Teva’s size a $57.5 million upfront is immaterial. The real value is the option on a first-of-its-kind at-home label, not near-term revenue.

What to watch next is the November 14 PDUFA decision, plus any competing bids in the auction that could push the price above Teva’s stalking-horse floor. The main risk is an FDA request for more data or a rejection of the at-home label, which would gut the deal’s contingent value and leave creditors with only the upfront cash.

Source: BioXcel Therapeutics asset sale agreement with Teva press release